A Phase I and Phase II Study of OSI-774 [erlotinib] in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

A Phase I and Phase II Study of OSI-774 [erlotinib] in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2013

At a glance

  • Drugs Erlotinib (Primary) ; Docetaxel
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2007 Status changed from recruiting
    • 05 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top